NCT05597345 2025-02-10
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
University of Rochester
Phase 2 Recruiting
Clinical Trials
5 trialsNCT04782687 2025-01-16
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
Phase 2 Active not recruiting
NCT06212596 2024-01-19
MUKtwelve
University of Leeds
Phase 2 Completed
NCT04843579 2023-10-25
ClaSPd
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02186834 2023-01-04
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed